Brucella spp. Lumazine synthase as a novel immunomodulator to produce egg yolk antibodies英文文献资料.docVIP

Advances in Bioscience and Biotechnology, 2012, 3, 80-86 ABB /10.4236/abb.2012.31012 Published Online February 2012 (http://www.SciRP.org/journal/abb/) Brucella spp. Lumazine synthase as a novel immunomodulator to produce egg yolk antibodies Demian Bellido , Pablo Chacana , Marina Mozgovoj , Diego Gonzalez , Fernando Goldbaum , 1 1 1 1 2 1 1 Andrés Wigdorovitz , María José Dus Santos 1 2 Institute Instituto de Virología, INTA Castelar, Hurlingham, Argentina Fundación Instituto Leloir, Buenos Aires, Argentina Email: dbellido@.ar Received 12 October 2011; revised 22 November 2011; accepted 28 December 2011 ABSTRACT This strategy has demonstrated to be successful in the treatment and prophylaxis of diseases caused by bacteria, viruses or even parasites [2]. However, large scale pro- duction of mammalian antibodies is expensive and un- easy. To overcome these difficulties, egg yolk antibodies are proposed as a low-cost and feasible alternative [3]. Since the early 1980’s, egg yolk antibodies have been deeply studied [4,5]. IgY is the only immunoglobulin isotype present in the egg yolk, the main serum immu- noglobulin in birds and it is considered to be ancestral of mammals IgG and IgE [4]. The use, production and puri- fication of the egg yolk IgY is known as IgY technology [6]. IgY technology has several advantages over conven- tional mammalian antibody production: chicken housing is inexpensive, egg collection is noninvasive and IgY isolation is relatively fast and simple [7]. Moreover, due to the phylogenetic distance, conserved mammal proteins are often more immunogenic in birds than in mammals [8]. IgY technology has been evaluated for thera